Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
Displaying: 646 trials in your specialties ()
View trials across your selected specialties

Achilles Tendinopathy Treated With Training and Injections

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Achilles Tendinopathy
View Full Trial
INTERVENTION

Behavioral: Reduction in running and jumping, Other: Training, Drug: Ultrasound guided injection with Glucocorticosteroid, Drug: Ultrasound guided injection with local anaestethic

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Institute of Sports Medicine Copenhagen, Bispebjerg Hospital, København NV, Denmark

Brief Summary

The purpose of this study is to compare in a randomized double blinded controlled trial the effect of heavy slow resistance exercises combined with ultrasound guided injections with local anesthetic with or without glucocorticosteroid in patients with achilles tendinopathy.

Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Chronic Myeloid Leukemia
View Full Trial
INTERVENTION

Drug: Nilotinib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Novartis Investigative Site, Moers, Germany

Brief Summary

The main purpose of this study is evaluation of deep molecular response (MR4.5; BCR-ABL IS < 0.0032%) after 24 months of therapy with nilotinib in newly diagnosed patients with chronic phase CML. Via the use of MR4.5 EUTOS ('European Treatment and Outcome Study for CML') laboratories adequate and reliable molecular monitoring as a key parameter for assessing molecular milestones is fostered. Furthermore this trial aims to investigate early prediction of outcome in newly diagnosed patients with nilotinib by assessing the individual decline of BCR-ABL transcripts. Quality of life will bemeasured via use of the EORTC CML-24 questionnaire.

Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Plaque Psoriasis
View Full Trial
INTERVENTION

Radiation: nbUVB, Biological: Secukinumab, Biological: Secukinumab, Biological: Secukinumab, Biological: Secukinumab, Drug: Calcipotriol, Drug: Betamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina

Brief Summary

The purpose of this study is to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom free periods by preventing reactivation of old lesions or ultimately totally hindering the occurrence of new lesions, i.e., changing the natural course of the disease (Main Study).

Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Clostridium Difficile Infection
View Full Trial
INTERVENTION

Drug: Oral Vancomycin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Renown Regional Medical Center, Reno, Nevada, United States

Brief Summary

This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial infection.

Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Chronic Pain
View Full Trial
INTERVENTION

Drug: Morphine, Drug: Guanfacine 1mg, Drug: Guanfacine 2mg, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Center for Translational Pain Research, Boston, Massachusetts, United States

Brief Summary

Dual medication (guanfacine and morphine) as a standard treatment for chronic pain.

Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Atopic Dermatitis
View Full Trial
INTERVENTION

Drug: Crisaborole 2% Top Oint

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

MGH Clinical Unit for Research Trials in Skin (CURTIS), Boston, Massachusetts, United States

Brief Summary

The purpose of this study is to document the timing of improvement in atopic dermatitis symptoms and severity following the application of crisaborole ointment 2% in patients 2 years or older with mild to moderate atopic dermatitis. Crisaborole ointment 2% will be applied topically twice daily for four weeks and progress will be assessed by photography and patient-reports.

Effects of Switching From Racemic Methadone to R-methadone on QTc Intervals

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Adverse Drug Effect, Drug Effect, Heart Arrhythmia
View Full Trial
INTERVENTION

Drug: Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Department of Pharmacology , Oslo University Hospital, Oslo, Norway

Brief Summary

Effects of switching from racemic methadone to R-methadone on serum methadone concentrations and QTc intervals

Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Multiple Sclerosis
View Full Trial
INTERVENTION

Drug: Discontinuation of disease modifying therapy, Drug: Standard of Care

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of California, Los Angeles, California, United States

Brief Summary

Natural history research in Multiple Sclerosis (MS) suggests that risk of relapses and new Magnetic Resonance Imaging (MRI) changes diminish significantly as people age, especially in MS patients 55 or older. Thus, the need to continue MS medicines that reduce relapses and new MRI lesions may also decrease as people age, especially in those who have not had relapses or MRI scan changes for prolonged times. This study plans to learn more about the safety of stopping MS medication in this population, as compared to continuing on the medication.

Effect of Safinamide on Parkinson's Disease Related Chronic Pain

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Idiopathic Parkinson Disease
View Full Trial
INTERVENTION

Drug: Safinamide Methanesulfonate, Drug: Safinamide methanesulfonate matching placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Medizinische Universitat Innsbruck, Innsbruck, Austria

Brief Summary

This is a Phase IV, international, multicentre, randomised, double-blind, placebo controlled study in IPD patients, experiencing motor fluctuations and PD related chronic pain while on stable doses of levodopa (L-Dopa). Participants will be randomized 2:1 to receive either active or placebo

Second-generation Drug-eluting Stents in Diabetes

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Coronary Artery Disease, Diabetes Mellitus
View Full Trial
INTERVENTION

Device: Polymer-free amphilimus-eluting stents, Device: Biolinx Polymer-based zotarolimus-eluting stents

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Hospital Clínico de Valencia, Valencia, Spain

Brief Summary

This is an investigator initiated randomized trial, performed under the auspices of the Spanish Society of Cardiology. It is a multicenter, international, parallel, randomized 1:1 (amphilimus-eluting stents vs zotarolimus-eluting stents) clinical trial performed exclusively in patients with diabetes mellitus. The study has an "all-comers diabetics" design. The primary-endpoint is target lesion failure at 1-year follow-up (non-inferiority design) and the co-primary end-point is target lesion failure at 2-years follow-up (superiority-design).